Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Delirium is a common and serious condition and is associated with adverse outcome. The elderly who have cognitive dysfunction are expected to show delirium more frequently. It is most likely that delirium represents a response to impaired cholinergic neurotransmission. Investigators aimed to establish the preventive effect of the cholinesterase inhibitor, rivastigmine patch, on the post-operative delirium limited to femur neck fracture operation in patients at risk of dementia.
Investigators evaluated the delirium prevention effect of rivastigmine patch in patients with femur neck fracture and cognitive impairment. Investigators measured the frequency and severity of post-operation delirium in the patch applied and non-applied subjects.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patch applied patients | Experimental | The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture. Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation. |
|
| Patch non-applied patients | No Intervention | The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rivastigmine patch | Drug | acetylcholine esterase inhibitor |
|
| Measure | Description | Time Frame |
|---|---|---|
| the number of participants with delirium | investigators evaluated the delirium frequency in rivastigmine applied participants comparing with non-applied participants. | up to 7th days |
| Measure | Description | Time Frame |
|---|---|---|
| delirium severity using delirium rating scale | to compare the severity of delirium in rivastigmine patch applied participants with non-applied | up to 7th days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Young Chul Youn, MD, PhD | Dept of Neurology, Chung-Ang University Hospital | Principal Investigator |
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jul 24, 2015 | |
| Reset | Aug 18, 2015 | |
| Release | Jul 23, 2019 | |
| Reset | Aug 12, 2019 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jul 24, 2015 | Aug 18, 2015 | |||
| Jul 23, 2019 |
| ID | Term |
|---|---|
| D003693 | Delirium |
| ID | Term |
|---|---|
| D003221 | Confusion |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Aug 12, 2019 |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |